Shin Takayama

Shin Takayama

Auto-generated profile, based on publicly available information

Shin Takayama

Department of Breast Surgery, National Cancer Center Hospital, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
CWChikashi Watase
Chikashi Watase
SSSho Shiino
Sho Shiino
TSTatsunori Shimoi
Tatsunori Shimoi
ENEmi Noguchi
Emi Noguchi
TKTomoya Kaneda
Tomoya Kaneda
ASAkihiko Suto
Akihiko Suto
Breast cancer is the second most common origin of brain metastasis after lung cancer. Brain metastasis in breast cancer is commonly found in patients with advanced course disease and has a poor prognosis because the blood–brain barrier is thought to be a major obstacle to the delivery of many drugs in the central nervous system. Therefore, local treatments including surgery, stereotactic radiation therapy, and whole-brain radiation therapy are currently considered the gold standard treatments. Meanwhile, new targeted therapies based on subtype have recently been developed. Some drugs can exceed the blood–brain barrier and enter the central nervous system. New technology for early detection and personalized medicine for metastasis are warranted. In this review, we summarize the historical overview of treatment with a focus on local treatment, the latest drug treatment strategies, and future perspectives using novel therapeutic agents for breast cancer patients with brain metastasis, including ongoing clinical trials.

19 July 2022 in Cancer Research
Verified
Journal Article
Closed access
PDF file
MTMomoko Tokura
Momoko Tokura
JNJun Nakayama
Jun Nakayama
MPMarta Prieto-Vila
Marta Prieto-Vila
SSSho Shiino
Sho Shiino
MYMasayuki Yoshida
Masayuki Yoshida
YYYusuke Yamamoto
Yusuke Yamamoto
Ductal carcinoma in situ (DCIS) is a precursor to invasive breast cancer. The frequency of DCIS is increasing because of routine mammography; however, the biological features and intratumoral heterogeneity of DCIS remain obscure. To address this deficiency, we performed single-cell transcriptomic profiling of DCIS and invasive ductal carcinoma (IDC). DCIS was found to be composed of several transcriptionally distinct subpopulations of cancer cells with specific functions. Several transcripts, including long noncoding RNAs, were highly expressed in IDC compared with DCIS and might be related to the invasive phenotype. Closeness centrality analysis revealed extensive heterogeneity in DCIS, and the prediction model for cell-to-cell interactions implied that the interaction network among luminal cells and immune cells in DCIS was comparable with that in IDC. In addition, transcriptomic profiling of HER2+ luminal DCIS indicated HER2 genomic amplification at the DCIS stage. These data provide novel insight into the intratumoral heterogeneity and molecular features of DCIS, which exhibit properties similar to IDC. Significance: Investigation of the molecular features of ductal carcinoma in situ at single cell resolution provides new insights into breast cancer biology and identifies candidate therapeutic targets and diagnostic biomarkers.

1 January 2019 in International Journal of Surgery Case Reports
Verified
Journal Article
Open access
STShin Takayama
Shin Takayama
KSKaishi Satomi
Kaishi Satomi
MYMasayuki Yoshida
Masayuki Yoshida
CWChikashi Watase
Chikashi Watase
TMTakeshi Murata
Takeshi Murata
ASAkihiko Suto
Akihiko Suto
Introduction: Spontaneous regression of a malignant tumor is defined as “the partial or complete disappearance of a malignant tumor in the absence of any treatment.” Herein, we report a case of occult breast cancer with axillary lymph node metastasis that showed spontaneous tumor regression based on the histopathological findings. Presentation of the case: A 67-year-old woman presented with left armpit pain and a lump. Previous examination by another doctor revealed swelling of the left axillary lymph node, but it was difficult to identify the primary lesion. Needle biopsy of the left axillary lymph node revealed malignant tumor tissue with extensive necrosis on histological examination. On initial examination at our hospital, the left axillary lymph node was observed to have shrunk compared to previous observations. Moreover, findings indicated a suspected concentrated cyst in the left breast, with slight contrast enhancement on magnetic resonance imaging. Considering a diagnosis of occult breast cancer with axillary lymph node metastasis, excisional biopsy was performed for the left breast mass and axillary lymph node dissection for left axillary lymph node metastasis. Histological examination revealed a micro adenocarcinoma with lymphocyte infiltration in the left breast, and the viable tumor in the left axillary lymph node had disappeared. The histopathological findings of the primary tumor and dissected lymph nodes suggested the possibility of spontaneous regression of both the primary and metastatic lesions, because effective preoperative therapy was not performed. Highlights:

1 January 2023 in JMA Journal
Verified
Journal Article
Open access
STShin Takayama
Shin Takayama
TKTakayuki Kinoshita
Takayuki Kinoshita
SSSho Shiino
Sho Shiino
KJKenjiro Jimbo
Kenjiro Jimbo
KWKen-Ichi Watanabe
Ken-Ichi Watanabe
ASAkihiko Suto
Akihiko Suto
Due to the increase in the number of early-stage breast cancer patients, there is growing interest in minimally invasive local therapies for breast cancer. Radiofrequency ablation (RFA) therapy is one of the most promising minimally invasive treatments. The Radiofrequency Ablation Therapy for Early Breast Cancer as Local Therapy (RAFAELO) study, a multicenter collaborative study that aims to validate the efficacy and safety of RFA and to standardize its use for early-stage breast cancer, was conducted under the Advanced Medical Care B system in 2013. This study enrolled the expected number of patients in November 2017; moreover, it is currently in the follow-up period. Some patients with early-stage breast cancer who are eligible for RFA could not receive the RFA treatment, as it is still not covered by insurance. Therefore, the Patients Offer Radiofrequency Ablation Therapy for Early Breast Cancer as Local Therapy (PO-RAFAELO) study under the Patient-proposed Health Services (PPHS) was proposed and approved in March 2019. The PPHS is a system that allows patients to receive prompt access to advanced medical care at a medical facility close to them, starting with their request. This system is considered a part of the specific and special medical coverage. The PO-RAFAELO study is the only study in the surgical field utilizing the PPHS, aiming to help in achieving regulatory approval and insurance coverage of RFA for breast cancer. As of January 2023, 120 patients have undergone RFA using the PPHS and no grade 3 or higher early adverse events have occurred. A certain number of patients with early-stage breast cancer prefer nonsurgical treatment, and it is important to provide information regarding the availability of RFA for early-stage breast cancer under the PPHS. Trial registration: registered with Japan Registry of Clinical Trial on March 06, 2019 (Trial ID: jRCTs032180187).

2 September 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AHAi Hironaka-Mitsuhashi
Ai Hironaka-Mitsuhashi
ACAnna Sanchez Calle
Anna Sanchez Calle
TOTakahiro Ochiya
Takahiro Ochiya
STShin Takayama
Shin Takayama
ASAkihiko Suto
Akihiko Suto
In the era of precision medicine, targeted therapies have been implemented for various diseases. Genomic information guides decision-making in cancer treatment. The improvements in next-generation sequencing and polymerase chain reaction have made it possible to access the genetic information using circulating-tumor DNAs (ctDNAs). Molecular characteristics of individual tumors can be obtained by analysis of ctDNAs, thus making them excellent tools to guide decision-making during treatment. In oncology, the use of ctDNAs in clinical practice is now gaining importance. Molecular analysis of ctDNAs has potential for multiple clinical applications, including early diagnosis, prognosis of disease, prognostic and/or predictive biomarkers, and monitoring response to therapy and clonal evolution. In this paper, we highlight the applications of ctDNAs in cancer management, especially in metastatic setting, and summarize recent studies about the use of ctDNAs as predictive biomarkers for the therapeutic adaptation/response in lung cancer, breast cancer, and colorectal cancer. These studies offer the evidence to use ctDNAs as a promising approach to solve unmet clinical needs.

1 August 2021 in Clinical Breast Cancer
Verified
Journal Article
Open access
TMTakeshi Murata
Takeshi Murata
CWChikashi Watase
Chikashi Watase
SSSho Shiino
Sho Shiino
KJKenjiro Jimbo
Kenjiro Jimbo
EIEriko Iwamoto
Eriko Iwamoto
ASAkihiko Suto
Akihiko Suto
It has been determined that axillary lymph node dissection after the detection of limited axillary lymph node metastasis does not improve the prognosis of patients with breast cancer. Thus, a need exists for less-invasive axillary surgery. However, it remains unclear whether a predictive model based on preoperative data would be sufficient to accurately predict the probability of pN2-N3 (> 3 lymph node metastases). We sought to develop an easy-to-use scoring system to distinguish between pN0-N1 (0-3 lymph node metastases) and pN2-N3 using only preoperative data and validate its predictive performance. We retrospectively identified 2687 patients diagnosed with cT1-3cN0-N1 who had undergone surgery in our hospital from 2013 to 2019. We evaluated the risk factors associated with pN2-N3 by logistic regression analysis and developed a scoring system. Predictive performance was assessed by calculating the receiver operating characteristic area under the curve (AUC) and was validated using K-fold cross-validation. We identified 1987 patients with stage pN0, 522 with pN1, and 178 with pN2-N3. Multivariate analysis revealed tumor size, number of suspicious lymph nodes on axillary ultrasound examination, histologic type, histologic grade, and receptor status were significant risk factors for pN2-N3. The AUC value was 0.87, and the mean AUC of the 10-fold cross-validation was 0.88. When the cutoff score was set at 6, the negative predictive value for excluding patients with pN2-N3 was 98.4%. Our easy-to-use scoring system could be useful to preoperatively identify patients at lower risk of pN2-N3 and avoid unnecessary axillary lymph node dissection.